2223 ⎘
Animals characterised by purpose; Animal model, e.g. for test or diseases; Animal model for multifactorial diseases Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
VIRAL EXPRESSION CONSTRUCT COMPRISING A FIBROBLAST GROWTH FACTOR (FGF21) CODING SEQUENCE
#2USE OF AKR1C3 INHIBITOR IN PREPARATION OF DRUG FOR TREATING OR PREVENTING METABOLIC ASSOCIATED FATTY LIVER DISEASE
#3GENE THERAPY FOR HAPLOINSUFFICIENCY
#4HUMANIZED MOUSE MODELS FOR ASSESSING IMMUNE CELL THERAPY
#5TRANSGENIC MOUSE
#6DELIVERY AND USE OF THE CRISPR-CAS SYSTEMS, VECTORS AND COMPOSITIONS FOR HEPATIC TARGETING AND THERAPY
#7CORRECTION OF HEPATOSTEATOSIS IN HUMANIZED LIVER ANIMALS THROUGH RESTORATION OF IL6/IL6R/GP130 SIGNALING IN HUMAN HEPATOCYTES
#8VIRAL EXPRESSION CONSTRUCT COMPRISING A FIBROBLAST GROWTH FACTOR 21 (FGF21) CODING SEQUENCE
#9CORRECTION OF HEPATOSTEATOSIS IN HUMANIZED LIVER ANIMALS THROUGH RESTORATION OF IL6/IL6R/GP130 SIGNALING IN HUMAN HEPATOCYTES
#10METHODS AND COMPOSITIONS FOR THE TARGETED MODIFICATION OF A GENOME
#11MURINE-MHC-DEFICIENT HLA-TRANSGENIC NOD-MOUSE MODELS FOR T1D THERAPY DEVELOPMENT
#12GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC GLP1R
#13Method of treating rheumatoid arthritis using antibodies to oxidized phospholipids
#14TRANSGENIC MOUSE MODELS SUPPORTING HUMAN INNATE IMMUNE FUNCTION
#15METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROLOGIC DISEASE
#16INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES MELLITUS
#17Gene therapy for haploinsufficiency
#18TRANSGENIC MOUSE MODEL EXPRESSING HUMAN HLA-A201 RESTRICTION GENE
#19COMPLEXES FOR GENE DELETION AND EDITING
#20TRANSCRIPTION MODULATION IN ANIMALS USING CRISPR/CAS SYSTEMS
#21COMPOSITIONS AND METHODS FOR REGULATING FATTY ACIDS
#22Compositions and methods for treatment of GCase related disease states
#23METHOD FOR ESTABLISHING DIABETES DISEASE MODEL DOG
#24METHODS AND COMPOSITIONS FOR THE TREATMENT OF PRE-DIABETES, DIABETES AND METABOLIC SYNDROME
#25Humanized mouse models for assessing immune cell therapy
#26Method for integrating biological tissues with a vascular system
#27NON-HLA MATCHED HUMANIZED NSG MOUSE MODEL WITH PATIENT-DERIVED XENOGRAFT
#28NON-HLA MATCHED HUMANIZED NSG MOUSE MODEL WITH PATIENT-DERIVED XENOGRAFT
#29METHODS FOR PREVENTING AND TREATING TYPE II DIABETES
#30Targeted modification of rat genome
#31A RODENT MODEL OF B4GALT1-MEDIATED FUNCTIONS
#32Delivery and use of the CRISPR-CAS systems, vectors and compositions for hepatic targeting and therapy
#33Methods for preventing and treating type II diabetes
#34Compositions and methods for treatment of GCASE related disease states
#35Methods and compositions for the targeted modification of a genome
#36Therapeutic compositions
#37METHOD FOR CONSTRUCTING MOUSE MODEL WITH CONDITIONAL KNOCKOUT OF TMEM30A GENE FROM PANCREATIC BETA CELL, AND USE THEREOF
#38USE OF CREG IN TREATMENT OF NONALCOHOLIC FATTY LIVER DISEASE AND TYPE 2 DIABETES
#39VIRAL EXPRESSION CONSTRUCT COMPRISING A FIBROBLAST GROWTH FACTOR 21 (FGF21) CODING SEQUENCE
#40Transgenic C57BL6-BTBR mouse with a humanized MHC II gene that expresses GAD65
#41Gene therapy for haploinsufficiency
#42Application of GPR45 gene
#43Targeted modification of rat genome
#44Complexes for gene deletion and editing
#45Mouse Models Having a Knockin Scavenger Receptor Class B Type I
#46Transcription modulation in animals using CRISPR/Cas systems
#47Therapeutic compositions
#48Adenoassociated virus vectors for the treatment of mucopolysaccharidoses
#49METHOD FOR ESTABLISHING A NON-HUMAN MAMMALIAN ANIMAL MODEL SUFFERING FROM OBESITY OR RELATED DISEASE AND USE THEREOF
#50Compositions and methods for treating and preventing metabolic disorders
#51Use of C1q/TNF-related protein-1 (CTRP1) to treat fatty liver disease
#52Non-Human Animals Comprising SLC30A8 Mutation And Methods Of Use
#53STEM CELLS FOR MODELING TYPE 2 DIABETES
#54Methods and compositions for the targeted modification of a mouse ES cell genome
#55Murine-MHC-deficient HLA-transgenic nod-mouse models for T1D therapy development
#56Oncogenic Models Based on Delivery and Use of the CRISPR-Cas Systems, Vectors and Compositions
#57Transgenic cloned piglet expressing human proinsulin and method of producing the same
#58Anti-obesity microbiota compositions and preparation methods and uses thereof
#59LDL receptor gene knockout, genetically-engineered hamster
#60Use of guaiacol for the prevention and treatment of glycogen storage disease
#61Animal models for nonalcoholic fatty liver disease
#62Antibodies to oxidized phospholipids
#63Antibodies to oxidized phospholipids
#64A MOUSE MODEL OF NONALCOHOLIC STEATOHEPATITIS AND USES THEREOF
#65Antibodies to oxidized phospholipids
#66Delivery, use and therapeutic applications of the CRISPR-cas systems and compositions for modeling mutations in leukocytes
#67Compositions and methods for treatment of Gcase related disease states
#68PCSK9 INHIBITORY POLYPOLYPEPTIDES AND METHODS OF USE
#69INHIBITING CTRP5 ACTION TO IMPROVE INSULIN RESISTANCE ASSOCIATED WITH OBESITY AND TYPE 2 DIABETES
#70Non-HLA matched humanized NSG mouse model with patient-derived xenograft
#71Compounds capable of antagonizing islet amyloid polypeptide (IAPP) induced beta-cell damage and impaired glucose tolerance
#72Non-obese diabetes mice and its applications
#73Disease model pig exhibiting stable phenotype, and production method thereof
#74Methods and compositions for the treatment of pre-diabetes, diabetes and metabolic syndrome
#75Therapeutic compositions
#76Pig model for diabetes
#77Targeted modification of rat genome
#78Transgene construct encoding delta 12 fatty acid
#79MUTATION FOR TYPE I DIABETES MELLITUS AND ANIMAL MODEL
#80APPLICATION OF GPR45 GENE
#81Methods and compositions for the targeted modification of a mouse embryonic stem cell genome
#82Mouse model of hyperuricemia
#83SorCS1 for the treatment of obesity
#84Methods for treating diet-induced obesity by decreasing or inhibiting P2Y2 purinergic receptor expression or activity
#85Method for selectively inhibiting ACAT1 in the treatment of obesity, metabolic syndrome, and atherosclerosis
#86TRANSGENIC MOUSE MODELS FOR MC4R
#87Multi-transgenic pigs for diabetes treatment
#88Stem cells for modeling type 2 diabetes
#89THERAPEUTIC PARASITE PREPARATION AND METHODS OF MAKING AND USING
#90Delivery and use of the CRISPR-Cas systems, vectors and compositions for hepatic targeting and therapy
#91Therapeutic compositions
#92TGIF2-induced reprogramming of hepatic cells to pancreatic progenitor cells and medical uses thereof
#93SorCS1-like agent for use in the treatment of insulin resistance and diseases related thereto
#94Sulfated-oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation
#95Animal model for type 2 diabetes and obesity
#96Reversibly masked polymers
#97Composition and methods for the prevention and treatment of diet-induced obesity
#98Methods for producing a population of pancreatic beta-cells
#99Obesity animal model and methods for making and using thereof
#100Methods of treating metabolic disease
#101Methods and compositions for the targeted modification of a mouse genome
#102TRANSGENIC MOUSE MODELS FOR MC4R
#103Methods and compositions for the treatment of insulin-associated medical conditions
#104Transgenic mouse expressing human apo(a) and human apo(B-100) with disabled vitamin C gene produces human Lp(a)
#105Mito-Ob: a transgenic mouse model for obesity
#106Method of treating a metabolic disorder induced by obesity in a subject in need thereof by administering MK2/3 inhibitors
#107Therapeutic compositions
#108Production of a human beta cell line from an early post natal pancreas
#109Enhancing a population of insulin releasing cells using GFR α-1 agonists
#110WDR13 as a novel biomarker useful for treating diabetes and cancer
#111Methods for treating metabolic syndrome with Cthrc1 polypeptide
#112Plasma anti-diabetic NUCB2 peptide (pladin) and uses thereof
#113Screening method for antidiabetic agent using newly identified insulin secretion regulation factor
#114Stat5b transgenic mice and methods of use thereof
#115Animal models of atherosclerosis
#116Establishment of rhesus monkey model of autoimmunity type 1 diabetes
#117Use of Follistatin-Like Related Gene (FLRG) to Increase Muscle Mass
#118TREATMENT OF OBESITY
#119NOVEL GENE DISRUPTIONS, COMPOSITIONS AND METHODS RELATING THERETO
#120Sulfated oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation
#121Non-human mammalian animal model for type 2 diabetes
#122Polyconjugates for in vivo delivery of polynucleotides
#123MO-1 conditional knock-out non-human animal and uses thereof
#124SorCS1 for the treatment of obesity
#125Methods of identifying candidate compounds of the human G protein-coupled receptor, GPR50, as modulators of body mass or adiposity
#126COMPOSITIONS RELATING TO A PHOSPHOPROTEIN AND METHODS OF USE
#127METHODS OF MONITORING ENDOPLASMIC RETICULUM (ER) STRESS RESPONSE
#128SorCS1-like agent for use in the treatment of insulin resistance and diseases related thereto
#129TRUNCATED ACTIVIN TYPE II RECEPTOR AND METHODS OF USE
#130Use of Guanylyl Cyclase C Agonists to Suppress Appetite
#131Method and kit for evaluation of predisposition to development of obesity, anti-obesity agent and method for screening thereof, non-human animal, adipose tissue, adipocyte, method for production of transgenic mouse, antigen, and antibody
#132ENPP1 (PC-1) GENE HAPLOTYPE ASSOCIATED WITH THE RISK OF OBESITY AND TYPE 2 DIABETES AND THEIR APPLICATIONS
#133Recombinant vectors and hosts comprising human glucokinase encoding gene
#134INHIBITING OBESITY PROGRESSION BY INHIBITING ADIPOCYTE DIFFERENTIATION WITH A PRE-ADIPOCYTE AUTOPHAGY INHIBITOR
#135Therapeutic compositions
#136Peptides that target dorsal root ganglion neurons
#137Gene disruptions, compositions and methods relating thereto
#138NOVEL GPR101 TRANSGENIC MICE AND METHODS OF USE THEREOF
#139Compositions and methods for decreasing type III deiodinase activity to modulate adiposity and blood glucose levels
#140DEFICIENCY IN THE HISTONE DEMETHYLASE JHDM2A RESULTS IN IMPAIRED ENERGY EXPENDITURE AND OBESITY
#141Therapeutic uses of inhibitors of RTP801
#142ANIMALS WITH REDUCED BODY FAT AND INCREASED BONE DENSITY
#143Isolated antibodies against biologically active leptin-related peptides
#144Therapeutic compositions
#145ANIMAL MODEL FOR DIABETES
#146Multi-transgenic pigs for diabetes treatment
#147Truncated activin type II receptor and methods of use
#148Methods of treating eye diseases in diabetic patients
#149METHOD FOR CONTROLLING GLUCOSE UPTAKE AND INSULIN SENSITIVITY
#150Isolated antibodies against biologically active leptin-related peptides
#151Adropin deficient mice and uses thereof
#152Prophylactic or therapeutic agent for diabetic maculopathy
#153Models of atherosclerosis, hyperlipidemia, lipoprotein oxidation and blood vessel inflammation and methods for making and using them
#154Therapeutic compositions
#155Plasma anti-diabetic NUCB2 peptide (pladin) and uses thereof
#156Use of Nestafin-1 in the Treatment for Diabetes
#157DRAK2 EXPRESSION IS ASSOCIATED WITH DIABETES
#158Methods of increasing muscle mass using follistatin-like related gene (FLRG)
#159Method of treatment of diabestes or reduction in pancreatic beta-cells
#160Use of pleitrophin for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
#161Altered Activity of Toll-Like Receptors
#162METHODS OF TREATING DISORDERS ASSOCIATED WITH FAT STORAGE
#163Pig model for atherosclerosis
#164Regulation of lipid droplet formation by modulation of FIT1 and FIT2 and uses thereof
#165MO-1, A Gene Associated With Morbid Obesity
#166Animal having modification in MGAT2 gene
#167Transgenic non-human animals expressing a truncated activin type II receptor
#168Liver-directed gene therapy
#169HUMAN GLP-1 MIMETIBODIES, COMPOSITIONS, METHODS AND USES
#170Methods of identifying candidate compounds of the human G protein-coupled receptor, GPR50, as modulators of body mass or adiposity
#171Nonalcoholic steatohepatitis model rodent and fatty liver model rodent
#172Genetically Modified Animal and Use Thereof
#173Transgenic Pig with Diabetes and Method for Producing the Same
#174Stearoyl-CoA Desaturase 4 Gene
#175Methods and compositions for using sax2
#176Modified Dynorphin Expression in Animals and Identification of Compounds for Treatment of Obesity and Diabetes
#177Transgenic pig with altered incretin function
#178Diabetes Model Animal
#179Polymorphic GHSR nucleic acids and uses thereof
#180Conditional-stop dimerizable caspase transgenic animals
#181Truncated Activin Type II Receptor and Methods of Use
#182TRANSCRIPTION FACTOR ARNTL2 GENE AND EXPRESSION PRODUCTS THEREOF USED IN THE DIAGNOSIS, PREVENTION, AND TREATMENT OF TYPE 1 DIABETES
#183Use of Bridge-1 and activators and inhibitors thereof in the treatment of insulin deficiency and diabetes
#184Antigens Targeted by Pathogenic T Cells in Type 1 Diabetes and Uses Thereof
#185HBM variants that modulate bone mass and lipid levels
#186High throughput genetic screening of lipid and cholesterol processing using fluorescent compounds
#187Membrane active heteropolymers
#188AMPK Deficient Animals, Screening Methods, And Related Therapeutics And Diagnostics
#189CAP/SORBS1 AND DIABETES
#190ANIMAL MODELS FOR OBESITY AND NEURODEGENERATIVE DISEASES
#191Membrane active heteropolymers
#192Chicken growth differentiation factor-8
#1937B2 Knockout transgenic animals as models of endocrine disease
#194BISPECIFIC ANTIBODIES
#195Method for activating efferent sympathetic nerves innervating adipose tissues to improve obesity and symptoms associated therewith
#196Endosomolytic poly(acrylate) polymers
#197Endosomolytic poly(vinyl ether) polymers
#198Compounds and methods for reversible modification of biologically active molecules
#199Endosomolytic Modified Poly(Alcohol) and Poly(Amine) Polymers
#200Reversibly Masked Polymers
#201Endosomolytic Poly-Beta-Aminoester Polymers
#202VASOACTIVE INTESTINAL POLYPEPTIDE COMPOSITIONS
#203Growth Differentiation Factor-8
#204Mouse developing visceral fat type obesity and diabetes
#205Enhancing a population of insulin releasing cells using GFR-A1 agonists
#206DISEASE MODEL ANIMALS OF METABOLIC SYNDROME AND A METHOD OF SCREENING PREVENTIVE AND THERAPEUTIC AGENTS FOR METABOLIC SYNDROME USING THE SAME
#207Growth Differentiation Factor-8 Nucleic Acid and Polypeptide from Aquatic Species, and Transgenic Aquatic Species
#208Polyconjugates for in vivo delivery of polynucleotides
#209Gene disruptions, compositions and methods relating thereto
#210DISEASE MODEL ANIMALS OF METABOLIC SYNDROME AND A METHOD OF SCREENING PREVENTIVE AND THERAPEUTIC AGENTS FOR METABOLIC SYNDROME USING THE SAME
#211Control Of Diabetes And Obesity
#212Mouse model of chronic heart failure and coronary atherosclerosis regression
#213Methods and Compositions Relating to Lipid Accumulation
#214Expression constructs expressing Prkag3
#215Pharmaceutical composition comprising a human GLP-1 mimetibody
#216Fluid flow meter body with high immunity to inlet/outlet flow disturbances
#217Methods for identifying candidate fat-mobilizing agents
#218Prophylactic or therapeutic agent for diabetic maculopathy
#219Methods of Validating Target for Modulating Insulin Action, Screening for Modulators of Insulin Action and Therapeutic Uses Thereof
#220Therapeutic compositions
#221Regulation of glucose and insulin levels by GnT-4 glycosyltransferase activity
#222Agents for Regulating Adiponectin Receptor Expression
#223Method of determining the susceptibility of a subject to developing insulin-dependent diabetes
#224Diabetes treatment methods and drug targets therefor
#225Use of soluble CD14 for treatment of type 2 diabetes mellitus
#226Isolated antibodies against biologically active leptin-related peptides
#227Type 2 diabetic non-human mammals and methods of use
#228Method for preventing and treating diabetes using dg119
#229Transgenic mice carrying the HP-2 gene and uses as models for vascular diseases
#230Perlecan transgenic animals and methods of identifying compounds for the treatment of amyloidoses
#231Sialidase inhibitors for the treatment of cardiovascular disease
#232Modulation of s6 kinase activity for the treatment of obesity
#233Cis-element regulating transcription, transcriptional regulatory factor binding specifically thereto and use of the same
#234Diabetes type 2 animal model
#235Transgenic animal having fatty acid desaturase and method of producing the same
#236Nucleic acid construct, metabolic disordered non-human animal and use thereof
#237Animals with reduced body fat and increased bone density
#238Methods of treatment of feeding disorders or disorders of glucose uptake and for modifying metabolism and identifying therapeutic reagents therefor
#239Protein Arginine N-Methyltransferase 2 (PRMT-2)
#240Treatment for diabetes
#241Gene-targeted animal model of apolipoprotein E4 domain interaction and uses thereof
#242Therapeutic uses of inhibitors of RTP801
#243Non-human animal models for diabetic complications and their uses
#244Method of screening drug
#245Minibrain homologous proteins involved in the regulation of energy homeostasis
#246Functional assays for cholesterol absorption inhibitors
#247GNG4 gene disruptions, compositions and methods related thereto
#248Method of screening antiobesity agents and animal model of obesity
#249Transgenic mice containing CX2 gene disruptions
#250Transgenic mice containing retinoid X receptor interacting protein gene disruptions
#251Animal model systems for viral pathogenesis of neurodegeneration, autoimmune demyelination, and diabetes
#252V1a arginine vasopressin receptor disruptions, compositions and methods relating thereto
#253Adiponectin-knoucout nonhuman animal
#254GPR54 knock-out mammals and screening methods using them
#255Stearoyl-CoA desaturase 4 gene
#256Non-human animal models of atherosclerosis and methods of use thereof
#257Transgenic non-human animals expressing a truncated activin type II receptor
#258OGH fusion polypeptides and therapeutic uses thereof
#259Inducible heart attack animal model
#260Growth differentiation factor-8 nucleic acid and polypeptide from aquatic species, and transgenic aquatic species
#261Modulators of dimethylarginine dimethylaminohydrolase and methods of use thereof
#262Compositions and methods of modulating cholesterol metabolism
#263Somatic cells, germ cells and cell lines derived from a PTTG knockout rodent
#264Polynucleotides encoding growth differentiation factor-8
#265Transgenic mouse expressing Prkag3
#266Transgenic animal model for chronic pancreatitis
#267Rat model of diabetic nephropathy
#268Methods and compositions for preventing obesity and obesity related disorders
#269Bispecific antibodies
#270Adipocytes and uses thereof
#271Transgenic RS1-/- animal and uses thereof
#272NaCT as a target for lifespan expansion and weight reduction
#2737B2 knockout transgenic animals as models of endocrine disease
#274HBM variants that modulate bone mass and lipid levels
#275Melanocortin-3 receptor deficient cells, non-human transgenic animals and methods of selecting compounds which regulate body weight
#276Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity and related disorders
#277Methods for identifying Rheb effectors as lead compounds for drug development for diabetes and diseases associated with abnormal cell growth